Wall Street Cuts Amgen, Lifts Micron

Analysts delivered a mixed bag of calls Wednesday. The standout moves span biotech, payments, and memory chips.

AMGN took the sharpest hit. A consensus downgrade pushed the biotech's analyst split to 5 buys against 17 holds. The average target price sits near $389. Amgen carries a $222 billion market cap. Short interest remains low at 2.2% of free float, so bears are not piling in yet.

MU got the opposite treatment. Analysts lifted their target price to $1,515 from $1,515 — a fractional but bullish nudge. Micron enjoys near-unanimous buy ratings. 44 analysts hold buy recommendations. The stock's free float short interest is just 2.6%.

GPN lost a recommendation entirely. One analyst removed their rating on Global Payments. The fintech name carries 12 buy ratings and 14 holds. Short interest here is more notable at 6.3% of free float. Consensus targets cluster around $104.

Jefferies trimmed its target on GE to $435 from $455 but kept a Buy rating. The aerospace giant still commands broad analyst support.

EQT saw a target price bump from analysts — a positive signal for the natural gas producer heading into winter.